Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1/2 2Phase 1 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NETWORK 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Breast Neoplasms 149Lymphoma 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Large B-Cell, Diffuse 46Leukemia 44Lymphoma, Follicular 39Lymphoma, Non-Hodgkin 35Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 28Leukemia, Myeloid, Acute 25Burkitt Lymphoma 24Neuroblastoma 21Lymphoma, Large-Cell, Immunoblastic 16Hodgkin Disease 16Lymphoma, Mantle-Cell 14Neoplasms 13Triple Negative Breast Neoplasms 12Lymphoma, B-Cell, Marginal Zone 11Sarcoma 10Inflammatory Breast Neoplasms 10Rhabdomyosarcoma 8Recurrence 8Neoplasms, Plasma Cell 8Myelodysplastic Syndromes 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Graft vs Host Disease 8Lymphoma, T-Cell, Peripheral 7Lymphoma, Large-Cell, Anaplastic 7Leukemia, Biphenotypic, Acute 7Lung Neoplasms 6

Interventions

dinutuximab 3Magnetic Resonance Spectroscopy 3Doxorubicin 3Cyclophosphamide 3Carboplatin 3Biopsy 3Vincristine 2Topotecan 2Thiotepa 2Temozolomide 2Stem Cell Transplantation 2Specimen Handling 2Radiation 2Platinum 2Melphalan 2Isotretinoin 2Irinotecan 2Etoposide 2Cisplatin 21,2-diaminocyclohexaneplatinum II citrate 2sargramostim 1lorlatinib 1etoposide phosphate 1Watchful Waiting 1Transurethral Resection of Bladder 1Razoxane 1Radiotherapy 1Observation 1Nuclear Medicine Department, Hospital 1Leukapheresis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Ganglioneuroblastoma × Cyclophosphamide × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT02176967 2026-05-05

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Children's Oncology Group

Phase 3 Active not recruiting
621 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡